Get started

Medicaldevices

Baxter International | BAX | Long at $35.00Baxter International NYSE:BAX , a company that primarily focuses on products to treat kidney disease and other chronic and acute medical conditions, is another name that had a very rough time through 2022 and into 2024. However, the company's projected earnings and cash flow are expected to grow from 2024 through 2027 and it currently has a 3.35% dividend. Interest rates being lowered soon will help these projections. From a technical analysis perspective, my selected simple moving average is working its way down to recapture the price for a likely reversal in the next year or two (unless company fundamentals change). The recent low in June 2024 was higher than the previous low in October 2023 (higher lows) indicating a high chance of future price improvement - but nothing is guaranteed. At $35.00, it is currently in a personal buy zone. Target #1 - $40.00 Target #2 - $48.00 Target #3 - $51.50 Target #4 - $65.00 Target #5 - $77.00 (very long-term...)
NYSE:BAXLong
by NicksAnalysis
AHCO | Good Long Entry | LONGAdaptHealth Corp., together with its subsidiaries, provides home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, including CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps to patients for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs. It serves beneficiaries of Medicare, Medicaid, and commercial insurance payors. The company is headquartered in Plymouth Meeting, Pennsylvania.
NASDAQ:AHCOLong
by DivergenceSeeker
1
BAX | Catch the Falling Knife | LONGBaxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
NYSE:BAXLong
by DivergenceSeeker
3
OWLT | A Good Entry Point | LONGOwlet, Inc. operates as a digital parenting platform in the United States. The company's platform focuses on giving real-time data and insights to parents. Its products include Smart Sock, a baby monitor to track an infant's oxygen levels, heart rates, and sleep trends; Dream Sock, an app to assist children for better sleep; Cam, a video streaming app to hear and see baby from anywhere; and Dream Lab, an interactive online platform that assists families in building healthy sleep habits. The company also offers Dream Duo, a monitoring system for baby's sleeping habits and includes wearable sock monitor, HD video, and digital sleep coach. Owlet, Inc. was founded in 2012 and is based in Lehi, Utah.
NYSE:OWLTLong
by DivergenceSeeker
6
AVGR | Incoming Rally | SqueezeAvinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.
NASDAQ:AVGRLong
by DivergenceSeeker
MYO | Medical Devices Need Love | LONGMyomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
AMEX:MYOLong
by DivergenceSeeker
BIO | Medical Device Co | Good EntryBio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
NYSE:BIOLong
by DivergenceSeeker
JNJ bullish scenario:The technical figure Pennant can be found in the US company Johnson & Johnson (JNJ) at daily chart. Johnson & Johnson is an American multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government. The Pennant has broken through the resistance line on 23/05/2022, if the price holds above this level you can have a possible bullish price movement with a forecast for the next 6 days towards 184.37 USD. Your stop loss order according to experts should be placed at 172.71 USD if you decide to enter this position. Johnson & Johnson is now working to spin off its consumer health division and after the company entered a series of settlements for its part in the opioid crisis. First-quarter metrics were mixed, but the company's medical devices business had few declines. Now, the Dow index stalwart expects $94.8 billion to $95.8 billion in 2022 sales. That no longer includes prior expectations for $3 billion to $3.5 billion in Covid vaccine sales. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
NYSE:JNJLong
by legacyFXofficial
Quiet accumulation and pro traders in a bottom: SILKThis is a young public company that is forming a bottom with some quiet accumulation, well hidden in price, by the Dark Pools during the bottom formation. The accumulation may include ETF Developers as many medical devices are in accumulation mode. Pro traders are in the mix as well. Candlestick patterns, improving volume and Accum/Dist indicators confirm--see blue arrows. When the bottom completes and sustains above the red line, there will be strong support for an uptrend. This company has pioneered TCAR.
SLong
by MarthaStokesCMT-TechniTrader
ISRG consolidation then new highs or retest support?Just did a basic fib retracement on ISRG using that last low. Looks like the 50 fib line presents a consistent area of traffic and previous support. It tested the 236 fib area weeks ago and after managing to break through and hold, the stock made new highs. After failing to retest those highs at the end of the week, it settled back at the recent levels just shy of 950. That area has also been a short-term area of support. But does it hold these levels and bounce to retest ATH or is the retracement in effect heading back down closer to the 236 fib line? Have to see what comes with ISRG earnings during this next round. That 71.22% surprise last quarter didn't hurt but can it maintain the same pace now that things are beginning to normalize to some extent?
NASDAQ:ISRG
by PennyStocks101
Ontrak seems not to want to forget the prices of the pastThe company Ontrak has always proved to be an excellent partner for care centers, unfortunately in recent months one of their major customers has decided to abandon the contract with the company Ontrak. This has led to a rapid decline in prices, but the company is proving to have a good basis to start again, the technology they produce is essentially unique and at the top of the category. Currently Ontrak comes defined 'heavy undervalued' in the sites of reference that I use for the fundamental analysis that is the price of the action turns out to be 85.4% under to the just value. Maybe that’s why many big investors are coming back to invest in Ontrak, I find the indicator Miracle Viewer that detects the flows of money categorizing them by type of players. And that’s why the Market miracle advisor gave an input signal on Ontrak at the price of 31.19 usd and a target of 35.98 usd or with a possible profit of 15.37% Analyzing the diagram is clear as it is drawing a reversal to U slightly in climb that testifies the strong pressure of purchase on the Stock. Looking at the cyclical nature of the big players I expect that in the coming weeks or at most within the next month the purchase pressure increases further, so I venture to make a further forecast for a second possible target. This idea is based on the signal generated by the Marketmiracle advisor whose link you can find by scrolling at the bottom of this page.
NASDAQ:OTRKLong
by MarketMiracleAdvisor
INMD Good Entry... INMD Inmode Ltd is an Israel-based company. It designs, develops, manufactures and commercializes energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. The Company’s proprietary technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including fat reduction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments... Tech that might help with those Covid lbs... Medical Devices group looking good ... Only concern is the lack of volume but some leaders have been breaking out on less than average volume for example, check out my NET Cloudflare entry. IBD #1 in its group Composite Rating 99 EPS Rating 98 RS Rating 96 Group RS Rating A- SMR Rating A Acc/Dis Rating A- Entry: 93.6 Stop 85.73 1R 7.61 Target 3R 116.43 Earnings due 8/5/21 Good space to run up to earnings report. 1R 7.61 Not trading advice. Educational purposes. Do your own due diligence.
NASDAQ:INMDLong
by Tea-Trades
2
ALGNAlign Technology, Inc. is a global medical device company with industry-leading innovative products such as Invisalign clear aligners, iTero Intraoral scanners, and OrthoCAD digital services that help dental professionals achieve the clinical results they expect and deliver effective, cutting-edge dental options to their patients. Approaching ATH Stage 2/26wks/Sector 62% in stage 2 Earnings date 1/27 Beat est last 3 quarters Risk 9% 12 wk base before gapping up Forming new base with two 9% shakeouts
NASDAQ:ALGNLong
by Tea-Trades